Ukko
Palo Alto
About Ukko
Ukko is a biotech firm focused on creating safe immunotherapies for quickly addressing allergies and other immune-related disorders. The company utilizes a unique technology platform that combines computational protein design with mRNA/LNP delivery to alter allergenic proteins. This approach seeks to mitigate or eliminate the risks of severe allergic reactions while eliciting a protective immune response. The Company is focused on changing the approach to prevent allergic reactions at the molecular level, striving to offer a safer and more targeted alternative to conventional desensitization techniques. This will lessen the treatment burden while meeting the critical needs of those vulnerable to severe allergic reactions to peanuts, with possibilities for extending the solution to other major allergens like milk, tree nuts, and respiratory triggers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $92.7M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2026)
- Website: ukko.us
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ukko-22324 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.